About: The contact activation system as a potential therapeutic target in patients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The contact activation system as a potential therapeutic target in patients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The contact activation system as a potential therapeutic target in patients with COVID‐19
Creator	Mccarty, J Faha, Jeffrey, \| Shatzel, Joseph Aslan, Joseph Gailani, David Gruber, Andras Lorentz, Christina Deloughery Bs, Emma Hinds Phd, Monica Owen, \| Tucker Phd, Erik Weitz, I
source	Medline; PMC; WHO
abstract	Coronavirus disease 2019 (COVID‐19) is predicted to overwhelm health care capacity in the United States and worldwide, and, as such, interventions that could prevent clinical decompensation and respiratory compromise in infected patients are desperately needed. Excessive cytokine release and activation of coagulation appear to be key drivers of COVID‐19 pneumonia and associated mortality. Contact activation has been linked to pathologic upregulation of both inflammatory mediators and coagulation, and accumulating preclinical and clinical data suggest it to be a rational therapeutic target in patients with COVID‐19. Pharmacologic inhibition of the interaction between coagulation factors XI and XII has been shown to prevent consumptive coagulopathy, pathologic systemic inflammatory response, and mortality in at least 2 types of experimental sepsis. Importantly, inhibition of contact activation also prevented death from Staphylococcus aureus–induced lethal systemic inflammatory response syndrome in nonhuman primates. The contact system is likely dispensable for hemostasis and may not be needed for host immunity, suggesting it to be a reasonably safe target that will not result in immunosuppression or bleeding. As a few drugs targeting contact activation are already in clinical development, immediate clinical trials for their use in patients with COVID‐19 are potentially feasible for the prevention or treatment of respiratory distress.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1002/rth2.12349
bibo:pmid	32542210
has license	cc-by-nc-nd
sha1sum (hex)	4ecf7625524660e5e0ffd39502be6dc753542fff
schema:url	https://doi.org/10.1002/rth2.12349
resource representing a document's title	The contact activation system as a potential therapeutic target in patients with COVID‐19
has PubMed Central identifier	PMC7264624
has PubMed identifier	32542210
schema:publication	Res Pract Thromb Haemost
resource representing a document's body	covid:4ecf7625524660e5e0ffd39502be6dc753542fff#body_text
is schema:about of	named entity 'cytokine' named entity 'sepsis' named entity 'release' named entity 'types' named entity 'activation' named entity 'prevention' named entity 'inflammatory response' named entity 'Contact' named entity 'mortality' named entity 'The contact' named entity 'consumptive coagulopathy' named entity 'worldwide' named entity 'decompensation' named entity 'drugs' named entity 'clinical trials' named entity 'prevent' named entity 'patients' named entity 'target' named entity 'respiratory distress' named entity 'Pharmacologic' named entity 'hemostasis' named entity 'inflammatory mediators' named entity 'consumptive coagulopathy' named entity 'host immunity' named entity 'pneumonia' named entity 'COVID-19' named entity 'coagulation factors' named entity 'decompensation' named entity 'coagulopathy' named entity 'FXI' named entity 'hemostasis' named entity 'FXI' named entity 'animal models' named entity 'mice' named entity 'FXI' named entity 'hereditary angioedema' named entity 'FXI' named entity 'Holstein cattle' named entity 'inflammatory cytokine' named entity 'deficient mice' named entity 'Pathologic' named entity 'coagulopathy' named entity 'FXI' named entity 'hepatic' named entity 'thromboprophylaxis' named entity 'factor XII' named entity 'recombinant' named entity 'antibody-mediated' named entity 'hepatic' named entity 'heparin' named entity 'pneumonia' named entity 'mouse model' named entity 'viral infections' named entity 'lungs' named entity 'KKS' named entity 'FXI' named entity 'peritoneal' named entity 'inflammation' named entity 'IL-6' named entity 'plasma' named entity 'host defense' named entity 'factor XI' named entity 'coagulation' named entity 'wild-type' named entity 'plasma' named entity 'inflammatory markers' named entity 'IL-6' named entity 'coagulation' named entity 'murine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software